Dr. Jeffrey A. Toretsky
Claim this profileMedStar Georgetown University Hospital
Studies Tumors
Studies Leukemia
18 reported clinical trials
48 drugs studied
Area of expertise
1Tumors
Stage I
Stage II
Stage IV
2Leukemia
NTRK1 positive
NTRK positive
BCR-ABL1 fusion positive
Affiliated Hospitals
Clinical Trials Jeffrey A. Toretsky is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Jeffrey A. Toretsky
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jeffrey A. Toretsky has experience with
- Cyclophosphamide
- Etoposide
- Laboratory Biomarker Analysis
- Cytology Specimen Collection Procedure
- Thioguanine
- Daunorubicin Hydrochloride
Breakdown of trials Jeffrey A. Toretsky has run
Tumors
Leukemia
Cancer
Lymphoblastic Leukemia-Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey A. Toretsky specialize in?
Jeffrey A. Toretsky focuses on Tumors and Leukemia. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage II.
Is Jeffrey A. Toretsky currently recruiting for clinical trials?
Yes, Jeffrey A. Toretsky is currently recruiting for 2 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey A. Toretsky has studied deeply?
Yes, Jeffrey A. Toretsky has studied treatments such as Cyclophosphamide, Etoposide, Laboratory Biomarker Analysis.
What is the best way to schedule an appointment with Jeffrey A. Toretsky?
Apply for one of the trials that Jeffrey A. Toretsky is conducting.
What is the office address of Jeffrey A. Toretsky?
The office of Jeffrey A. Toretsky is located at: MedStar Georgetown University Hospital, Washington, District of Columbia 20007 United States. This is the address for their practice at the MedStar Georgetown University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.